# Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

> **NCT00081302** · PHASE2 · COMPLETED · sponsor: **Radiation Therapy Oncology Group**

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00081302
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-12
- **Final completion:** 2013-11
- **Target enrollment:** — (—)
- **Last updated:** 2015-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081302, "Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00081302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*